



2891/3 (PHA4142.2)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Isakson et al.

Art Unit 1639

Serial No. 10/038,080

Filed January 03, 2002

Confirmation No. 7358

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED  
DISORDERS WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR  
AND A LEUKOTRIENE B<sub>4</sub> RECEPTOR ANTAGONIST

Examiner J. Epperson

March 19, 2003

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

**AMENDMENT C**

In response to the Office action mailed 21 November 2002, the time for response to which is extended to 21 March 2003, by the attached payment of the fee required under 37 C.F.R. §1.136(a), please enter the following amendment(s):

**IN THE CLAIMS:**

**Substitute claim 1 with the following:**

1. (once amended) A combination comprising a cyclooxygenase-2 selective inhibitor and a selective leukotriene B<sub>4</sub> receptor antagonist.

**Substitute claim 2 with the following:**

2. (three times amended) A combination comprising a selective leukotriene B<sub>4</sub> receptor antagonist and a cyclooxygenase-2 selective inhibitor selected from Taisho NS-398 (Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]), meloxicam (2H-1,2-

RECEIVED  
APR 01 2003  
TECH CENTER 1600/2900  
*[Handwritten signature]*  
4/12/03